Galapagos sells off Fidelta as CRO activities 'no longer fit with its strategy'

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 25, 2020 at 10:32 AM.

  1. #1 cafead, Nov 25, 2020 at 10:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,973
    Likes Received:
    3
    via Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

    The Krakow, Poland-based company is snapping up Fidelta as it looks to bolster its position as one of the largest preclinical CROs in Europe.

    Fidelta, with its R&D facilities based in Zagreb, Croatia, focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

    article source
     
    Quote

Reply to Thread